skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The Plasma Disappearance Time and Catabolic Half-Life of I131-Labelled Normal Human Gamma Globulin in Amyloidosis and in Rheumatoid Arthritis

Journal Article · · Journal of Clinical Investigation
DOI:https://doi.org/10.1172/JCI104418· OSTI ID:4839330

The serum survival time and catabclic half-life of intravenously injected I131-labeled pooled human gamma globulin - were studied in three patients with amyloidosis, four patients with rheumatoid arthritis, and three normal controls. The half-time of gamma globulin survival in the controsubjects ranged from 16.5 to 30 days. Two patients with amyloidosis, one primary and one secondary, both with the nephrotic syndrome, exhibited shortened serum half-times of 4.5 and 11 days, respectively. The serum half-time of the latter patient, before the appearance of clinical amyloidosis, was 14 days. One patient with primary amyloidosis but without nephrosis exhibited a half-time of serum gamma globulin disappearance of 21 days. The half-time of gamma globulin disappearance in four patients with chronic active rheumatoid arthritis varied between 19.5 and 8.5 days. The lower figure was found in a patient having a high titer of rheumatoid factor. If this subject is excepted, the average half- time in three rheumatoid subjects is 17 days. The catabolic half-life of the iodinated gamma globulin agreed in most instances with the serum half-time. The calculated distribution space of the injected gamma globulin showed no consistent alteration in either amyloidosis or rheumatoid arthritis as compared with the control subjects. Since the nephrotic syndrome from other causes may produce an accelerated catabolic half-life, a similar finding on these subjects cannot be ascribed to amyloidosis.

Research Organization:
Harvard Medical School, Boston, MA (United States); and Massachusetts General Hsopital, Boston
Sponsoring Organization:
USDOE
NSA Number:
NSA-15-031970
OSTI ID:
4839330
Journal Information:
Journal of Clinical Investigation, Vol. 40, Issue 10; Other Information: Orig. Receipt Date: 31-DEC-61; ISSN 0021-9738
Country of Publication:
Country unknown/Code not available
Language:
English